Avidity Partners 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 81 US equity positions worth $2.0bn in its Q3 2024 13F filing. The largest position was BSX at 4.1% of the reported book, followed by DNTH and ISRG. Against the Q2 2024 filing, it opened 10 new positions, added to 11 and reduced 26 among the top 50 holdings.
What did Avidity Partners own in Q3 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2024 |
|---|---|---|---|---|---|---|---|
| 1 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 4.1% | $80.6m | 962,000 | -18% | reduced |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 4.1% | $79.9m | 2,917,231 | 0% | held |
| 3 | ISRG INTUITIVE SURGICAL INC | Healthcare | 3.7% | $72.8m | 148,200 | -40% | reduced |
| 4 | NTRA NATERA INC | Healthcare | 3.6% | $70.6m | 556,400 | -27% | reduced |
| 5 | CGON CG ONCOLOGY INC | Healthcare | 3.2% | $62.5m | 1,656,000 | 28% | added |
| 6 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 3.2% | $62.5m | 985,000 | -12% | reduced |
| 7 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.7% | $53.0m | 460,000 | -6% | reduced |
| 8 | UNH UNITEDHEALTH GROUP INC | Healthcare | 2.6% | $51.1m | 87,400 | – | new |
| 9 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.4% | $48.0m | 431,000 | -21% | reduced |
| 10 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.4% | $47.3m | 2,455,000 | -26% | reduced |
| 11 | CATX PERSPECTIVE THERAPEUTICS INC | 2.3% | $46.0m | 3,444,002 | 13% | added | |
| 12 | GKOS GLAUKOS CORP | Healthcare | 2.3% | $44.9m | 344,900 | 54% | added |
| 13 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 2.2% | $43.5m | 1,373,000 | 23% | added |
| 14 | INSM INSMED INC | Healthcare | 2.2% | $43.2m | 592,000 | 38% | added |
| 15 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 2.2% | $42.4m | 68,600 | -14% | reduced |
| 16 | THC TENET HEALTHCARE CORP | Healthcare | 2.1% | $42.0m | 253,000 | -32% | reduced |
| 17 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.1% | $41.8m | 752,000 | -22% | reduced |
| 18 | HUM HUMANA INC | Healthcare | 2.1% | $41.1m | 129,700 | – | new |
| 19 | EXK EXACT SCIENCES CORP | Basic Materials | 2.0% | $40.1m | 588,000 | 74% | added |
| 20 | ILMN ILLUMINA INC | Healthcare | 1.9% | $38.1m | 292,000 | -39% | reduced |
| 21 | ARVN ARVINAS INC | Healthcare | 1.9% | $36.9m | 1,497,000 | -50% | reduced |
| 22 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.8% | $35.8m | 790,000 | 5% | added |
| 23 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.7% | $34.1m | 2,132,000 | – | new | |
| 24 | PHAT PHATHOM PHARMACEUTICALS INC | 1.7% | $32.6m | 1,804,493 | 11% | added | |
| 25 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.6% | $32.2m | 818,000 | 8% | added |
| 26 | AVTR AVANTOR INC | Healthcare | 1.6% | $31.9m | 1,235,000 | -60% | reduced |
| 27 | 2655787D BLUEPRINT MEDICINES CORP | 1.5% | $29.1m | 315,000 | -18% | reduced | |
| 28 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.5% | $28.5m | 731,104 | 0% | held |
| 29 | SGRY SURGERY PARTNERS INC | Healthcare | 1.4% | $26.7m | 827,000 | -37% | reduced |
| 30 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.4% | $26.6m | 296,100 | -21% | reduced |
| 31 | DHR DANAHER CORPORATION | Healthcare | 1.3% | $26.4m | 95,000 | -37% | reduced |
| 32 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.3% | $25.5m | 562,000 | -33% | reduced |
| 33 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 1.2% | $23.8m | 1,800,000 | 0% | held |
| 34 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 1.2% | $23.7m | 500,000 | – | new |
| 35 | BHVN BIOHAVEN LTD | Healthcare | 1.2% | $23.2m | 465,000 | 3% | added |
| 36 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 1.1% | $22.5m | 320,000 | – | new |
| 37 | ARGX ARGENX SE | Healthcare | 1.1% | $20.7m | 38,200 | -37% | reduced |
| 38 | INCY INCYTE CORP | Healthcare | 1.0% | $20.4m | 308,110 | -42% | reduced |
| 39 | ABBV ABBVIE INC | Healthcare | 1.0% | $19.7m | 100,000 | -64% | reduced |
| 40 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.0% | $19.4m | 790,926 | – | new |
| 41 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.0% | $18.9m | 430,900 | -60% | reduced |
| 42 | NGNE NEUROGENE INC | 0.9% | $17.8m | 425,041 | -42% | reduced | |
| 43 | 430 TERNS PHARMACEUTICALS INC | 0.9% | $17.8m | 2,133,872 | – | new | |
| 44 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.9% | $17.8m | 119,000 | – | new |
| 45 | BNTX BIONTECH SE | Healthcare | 0.9% | $17.2m | 145,000 | – | new |
| 46 | INTRA-CELLULAR THERAPIES INC | 0.9% | $17.0m | 233,000 | -42% | reduced | |
| 47 | KROS KEROS THERAPEUTICS INC | Healthcare | 0.9% | $17.0m | 293,200 | -15% | reduced |
| 48 | DXCM DEXCOM INC | Healthcare | 0.8% | $16.1m | 240,000 | -7% | reduced |
| 49 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.8% | $14.8m | 1,447,119 | – | new |
| 50 | NEWAMSTERDAM PHARMA COMPANY | 0.8% | $14.8m | 889,700 | 59% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.